Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H5O7.2Na.H |
| Molecular Weight | 236.0872 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=CEYULKASIQJZGP-UHFFFAOYSA-L
InChI=1S/C6H8O7.2Na/c7-3(8)1-6(13,5(11)12)2-4(9)10;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;/q;2*+1/p-2
| Molecular Formula | H |
| Molecular Weight | 1.0079 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H5O7 |
| Molecular Weight | 189.0997 |
| Charge | -3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU
Curator's Comment: Description was created based on several sources, including
http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU
Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0010447 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | UROCIT-K Approved UseUrocit®-K is a citrate salt of potassium indicated for the management of:
• Renal tubular acidosis (RTA) with calcium stones
• Hypocitraturic calcium oxalate nephrolithiasis of any etiology
• Uric acid lithiasis with or without calcium stones Launch Date4.94121615E11 |
|||
| Primary | UROCIT-K Approved UseUrocit®-K is a citrate salt of potassium indicated for the management of:
• Renal tubular acidosis (RTA) with calcium stones
• Hypocitraturic calcium oxalate nephrolithiasis of any etiology
• Uric acid lithiasis with or without calcium stones Launch Date4.94121615E11 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
540 mg 1 times / day multiple, oral Recommended Dose: 540 mg, 1 times / day Route: oral Route: multiple Dose: 540 mg, 1 times / day Co-administed with:: Thiamin oral 1.1 mg Sources: Page: p.2326Arginine oral 1240 mg caffeine oral 52 mg |
healthy, 24-59 n = 16 Health Status: healthy Age Group: 24-59 Sex: M+F Population Size: 16 Sources: Page: p.2326 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity. | 1985 Oct |
|
| Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate. | 1993 |
|
| [Therapeutic use of potassium citrate]. | 2001 |
|
| Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. | 2013 Jun |
Sample Use Guides
Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary
pH to a level of 6.0 to 7.0.
• Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
• Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:52 UTC 2023
by
admin
on
Fri Dec 15 15:01:52 UTC 2023
|
| Record UNII |
6FO62KCQ7A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C83678
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
6FO62KCQ7A
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
Disodium citrate
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
205-623-3
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
SUB21691
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
CONCEPT | Industrial Aid | ||
|
375
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
1366889
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | RxNorm | ||
|
6FO62KCQ7A
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
DTXSID50889423
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
SUB91628
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
8950
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | |||
|
m3595
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY | Merck Index | ||
|
144-33-2
Created by
admin on Fri Dec 15 15:01:52 UTC 2023 , Edited by admin on Fri Dec 15 15:01:52 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |